To return to the sitemap click this link.Sitemap

New hope for IBS sufferers
by: dave mcevoy

A recent clinical trial has given further weight to the acceptance that supplemented dietary nucleotides,
essential building blocks, can support the rapid production of new cells, which is beneficial for adult
immunity and gut health.

This 2005 clinical trial, the effectiveness of a nucleotide supplement in the management of individuals
with Irritable Bowel Syndrome (IBS), was sponsored by a grant from the Dept Trade and Industry, and conducted
at the University of East London, under control of Professor Christine Dancey. Professor Dancey heads the
Dept of Psychology and the Chronic Illness Research Team (CIRT) and is the co-founder of IBS Network.

IBS is one of the most prevalent chronic illnesses, and present’s itself through a number of symptoms.
The most severe cases generally include the following symptoms. Abdominal pain, varying from mild to
extremely severe this is the symptom which causes most sufferers to seek medical help. Diarrhoea, constipation
– or worse, an alternation of both are common. Urgency to have a bowel movement – also affects people
with constipation as well as diarrhoea, and a feeling of incomplete evacuation.

Current medical treatments are directed at symptomatic relief, and although these - and psychological
treatments - can help relieve IBS, there is no one treatment which has been shown to be lastingly effective.
Although IBS is not a life-threatening disease, the symptoms and the effects of the symptoms on daily life
can have a great impact on sufferers (Silk, 2001). IBS is also associated with large healthcare and
economic costs in terms of hospital investigations, repeated visits to GPs, prescription medicines, and
loss of time from work (Creed et al 2001).

Since there is no cure for IBS, people with IBS attempt to control their disorder by taking both prescribed
medicines and over-the-counter remedies, together with dietary control. Some are living on extremely
restricted, and therefore unhealthy, dietary regimes. In an earlier study of people with IBS, Dancey &
Backhouse (1993) found that 14% of their sample (N=148) ate very restricted diets hoping that this would
cure their IBS. However most of their sample (70%) said that they were trying to follow a healthy diet
with plenty of fruit and vegetables.

This clinical trial was carried out to determine whether a nucleotide supplement, could improve the symptoms
of IBS. Nucleotides are substances which are synthesised endogenously, and have important effects on the
growth and development of cells which have a rapid turnover, such as those in the immune system and the
gastrointestinal tract. In healthy people, dietary nucleotides are probably not essential, and in fact
most will be metabolised and rapidly excreted from the system. However, under certain circumstances e.g.
in the sub-well, diseased, or under conditions of stress or poor diet, dietary nucleotides may be what
Maldonado et al (2001) call “semi-essential", optimising the function of the gastrointestinal and immune
systems. In relation to the gastrointestinal system work has shown that dietary nucleotides enhance the
intestinal absorption of iron (Cosgrove 1998).

Holen & Jonsson (2004) found that dietary nucleotides had beneficial effects, especially when the nutrition
supply was inadequate. Work with infants has shown that the incidence and duration of acute diarrhoea is
lower in infants when dietary nucleotides are included in their diets (Gil, 2002). Research has shown the
benefits of dietary nucleotides in a variety of ways, and it would be expected that people with Irritable
Bowel Syndrome may benefit from nucleotide supplementation.

The chronic illness research team from the University of East London (Professor Dancey & colleagues) carried
out a double blind randomised placebo controlled study to determine whether there were any benefits of
nucleotide supplement on some of the common symptoms of IBS. Symptoms which bother participants the most
are pain, diarrhoea, and urgency to have a bowel movement.

Seven symptoms of IBS were analysed by the participants, who rated symptoms every day on a scale of 1
(“no discomfort at all today") to 7 (“very severe discomfort today"). All participants completed daily
diaries throughout the trial. After an initial 4 weeks baseline, they were allotted to condition A or
condition B. The capsules were taken three times a day with meals.

Psychological measures were taken at the beginning of the baseline period, the end of the experimental
condition and the end of the placebo condition. Depression was measured by the CES-D, suitable for non
clinical sample, and Anxiety measured by State-Trait. These are commonly used anxiety scales.

The drop-out rate for the trial was low. Participants dropped out for reasons other than adverse reactions
to the intervention in fact the placebo group had a higher drop out rate than the intervention groups.

Although there was a lot of variability with the daily scoring, it was clearly observed that symptoms
were lower for all symptoms in the nucleotide supplement compared with the placebo.

During the baseline period subjects symptom severity went up and down, but clearly during both the placebo
and with nucleotide supplement severity of symptoms improved. This improvement was more pronounced in the
nucleotide supplement group and also the improvement continued and grew over time. In other words, the
longer they took the nucleotide supplement the better they felt overall.

The strongest and most significant effects were observed for abdominal pain, urgency, incomplete evacuation
and diarrhoea.

Repeated measures analyses of variance were carried out for each symptom separately this involved finding
the mean of baseline measures, placebo and nucleotide supplement conditions. Compared to both baseline
and placebo conditions, the above symptoms are improved under the experimental condition (p<.05). Bloating
, and flatulence were not significantly improved at the p<.05 level.

It might be expected that due to the benefits of being in a clinical trial, anxiety and depression would
decrease over time. This was tested by a repeated measures analysis, comparing washout measures and end
of trial measures without considering condition (placebo or experimental). There were no differences.
There were also no significant differences in anxiety and depression between the 3 conditions.

The researchers concluded that the physical improvements observed were not due to psychological benefits
of being in a clinical trial.

Overall 23.73% of the participants improved by taking the nucleotide supplement. Also, the benefits of the
nucleotide supplement are greater than taking a placebo, the placebo effect usually being very high in
IBS trials.

Also, it was clear that the nucleotide supplement helps certain symptoms more than others – abdominal pain
, urgency to have a bowel movement, incomplete feeling of evacuation and diarrhoea. May be that a longer
trial would have shown larger effects, especially as the placebo response diminishes over time.

However, there was a definite effect of IntestAid IB, which is due to direct effects on the maintenance
and repair processes of the gastrointestinal system or by improvement in the gut immune function.
Copyright 2006 David McEvoy

-------- Dave Mcevoy is an award winning personal trainer he also runs a high quality supplement site
www.mind1st.com and www.mind1st.co.uk

More on IBS